Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
The goal of this study is to understand how the protein CD81 affects myeloid leukemia (especially AML) and whether it can help predict patient outcomes or guide treatment.
The main question it aims to answer:
Is high CD81 expression in myeloid leukemia cells linked to more aggressive disease, poorer treatment response, or shorter survival in patients?
Participants:
* Newly diagnosed myeloid leukemia patients (primary focus on AML) * Bone marrow or blood samples will be collected during routine diagnostic procedures
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Myeloid leukemia patients 2. Patients of both genders (Males and females) at any age 3. Cases are de novo (Not on treatment)
Disqualifiers
. Patients with other haematological neoplasms (ALL,CLL, plasma cell myeloma, etc)
Patients under any therapeutic intervention
Patients with current or previous other malignancies at time of diagnosis
Trial population
Myeloid leukemia patients
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
66 Participants
are grouped into 1 trial groupGroup A: study group
Trial outcomes
Primary outcomes
1
expression of CD81 in patients with myeloid leukemia
percentage of expression of CD81 in myeloid leukemia
Time frame
baselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: